Logo image
Olfactory neuroblastoma: the long-term outcome and late toxicity of multimodal therapy including radiotherapy based on treatment planning using computed tomography
期刊文章   同儕審查

Olfactory neuroblastoma: the long-term outcome and late toxicity of multimodal therapy including radiotherapy based on treatment planning using computed tomography

Takashi Mori, Rikiya Onimaru, Shunsuke Onodera, Kazuhiko Tsuchiya, Koichi Yasuda, Hiromitsu Hatakeyama, Hiroyuki Kobayashi, Shunsuke Terasaka, Akihiro Homma, Hiroki Shirato, …
Radiation oncology (London, England), 卷.10(1), 頁.88
15/04/2015
PMID: 25888953
Web of Science ID: WOS:000353110300001

摘要

Adult Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Combined Modality Therapy - adverse effects Esthesioneuroblastoma, Olfactory - mortality Esthesioneuroblastoma, Olfactory - secondary Esthesioneuroblastoma, Olfactory - therapy Female Follow-Up Studies Humans Male Middle Aged Nasal Cavity Neoplasm Recurrence, Local - mortality Neoplasm Recurrence, Local - pathology Neoplasm Recurrence, Local - therapy Neoplasm Staging Nose Neoplasms - mortality Nose Neoplasms - pathology Nose Neoplasms - therapy Postoperative Complications Prognosis Radiotherapy Planning, Computer-Assisted - methods Radiotherapy, Intensity-Modulated - adverse effects Retrospective Studies Survival Rate Tomography, X-Ray Computed - methods Young Adult
Olfactory neuroblastoma (ONB) is a rare tumor originating from olfactory epithelium. Here we retrospectively analyzed the long-term treatment outcomes and toxicity of radiotherapy for ONB patients for whom computed tomography (CT) and three-dimensional treatment planning was conducted to reappraise the role of radiotherapy in the light of recent advanced technology and chemotherapy. Seventeen patients with ONB treated between July 1992 and June 2013 were included. Three patients were Kadish stage B and 14 were stage C. All patients were treated with radiotherapy with or without surgery or chemotherapy. The radiation dose was distributed from 50 Gy to 66 Gy except for one patient who received 40 Gy preoperatively. The median follow-up time was 95 months (range 8-173 months). The 5-year overall survival (OS) and relapse-free survival (RFS) rates were estimated at 88% and 74%, respectively. Five patients with stage C disease had recurrence with the median time to recurrence of 59 months (range 7-115 months). Late adverse events equal to or above Grade 2 in CTCAE v4.03 were observed in three patients. Multimodal therapy including radiotherapy with precise treatment planning based on CT simulation achieved an excellent local control rate with acceptable toxicity and reasonable overall survival for patients with ONB.

檔案與連結 (1)

url
https://doi.org/10.1186/s13014-015-0397-5檢視
已出版(紀錄版本) 開放

相關連結

詳細資料

Logo image